The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...

Eli Lilly and Boehringer Ingelheim announced the launch of Basaglar (insulin glargine injection) for use to control high blood sugar in children and adults with type 1 diabetes and adults with type 2 ...

FDA Issues Complete Response Letter for Diabetes Drug The FDA has approved Basaglar (insulin glargine; Eli Lilly and Boehringer Ingelheim) injection to improve glycemic control in pediatric patients ...

Diabetics in late 2016 will to be able to buy a knockoff version of Lantus, the world's best-selling insulin, and it will be sold by Eli Lilly and Co. and its German partner. The Food and Drug ...

Original Medicare (Part A and Part B) does not cover insulin glargine (Basagalar). Medicare Part C and Part D cover some forms of insulin if you have diabetes, but coverage depends on the plan‘s ...

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is ...

Please provide your email address to receive an email when new articles are posted on . Among adults with type 2 diabetes, biosimilar insulin was noninferior to insulin glargine for lowering HbA1c, ...

Medicare Part D may cover Basaglar, a long-acting insulin, and under the Inflation Reduction Act, the cost should not exceed $35 per month. The availability of Basaglar under Medicare Part D depends ...